Cancer NetworkOriginal article
<![CDATA[FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma]]>
AdCompositiveRP1NivolumabPositive
AI Analysis
Summary
The FDA's Cancer Therapy and Immunotherapy Advisory Committee voted 10-3 in favor of RP1 combined with nivolumab for treating anti-PD-1-resistant advanced melanoma. This positive advisory committee recommendation supports the benefit-risk profile of the combination therapy.
Outcome Details
FDA CTGTAC voted 10-3 in favor of RP1 plus nivolumab's benefit-risk profile in anti-PD-1-resistant advanced melanoma
Importance:7/10
Sentiment:
0.80
FDA Advisory Committeemelanomaimmunotherapycombination therapyanti-PD-1 resistant
Read the original article
Published by Cancer Network on July 30, 2026 5:08 PM